Proximal predominance of small bowel injury associated with uncoated low-dose aspirin therapy: a video capsule study in chronic users.
Fiche publication
Date publication
novembre 2013
Auteurs
Membres identifiés du Cancéropôle Est :
Pr THIEFIN Gérard
Tous les auteurs :
Ehrhard F, Nazeyrollas P, Brixi H, Heurgue-Berlot A, Thiefin G
Lien Pubmed
Résumé
BACKGROUND AND AIM: Only a limited number of studies have evaluated the small intestinal damage associated with chronic low-dose aspirin (LDA) therapy. We assessed, using capsule endoscopy, the prevalence and the characteristics of small bowel damage in chronic LDA users compared with patients taking an anticoagulant (AC) and those taking no antithrombotic drugs. PATIENTS AND METHODS: We retrospectively reviewed 75 capsule endoscopy recordings from three groups of patients with unexplained iron-deficient anemia: 28 patients receiving LDA, 15 receiving an AC, and 32 not receiving any antithrombotic drug. The severity and location of small intestinal mucosal breaks were assessed in a blinded manner by two endoscopists. RESULTS: All LDA users received uncoated aspirin. The number of small bowel mucosal breaks in patients receiving LDA (median 1, extremes 0-125) was significantly higher than that in those taking an AC (0, 0-1) (P=0.0005) or no antithrombotic drugs (0, 0-23) (P
Référence
Eur J Gastroenterol Hepatol. 2013 Nov;25(11):1265-72